Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer

Phase 1

Completed

• Conditions: Castrate Resistent Prostate Cancer
• Interventions: Biological: BPX-201 vaccine plus AP1903

• Registration Number: NCT01823978
• Lead Sponsor: Bellicum Pharmaceuticals

Brief Summary

This is a Phase I, non-randomized, dose escalation study of the safety, biomarkers, and preliminary efficacy of dendritic cell vaccine, BPX-201, plus activating agent, AP1903, in patients with metastatic castrate resistant prostate cancer.

Detailed Description

This is a Phase I study of therapeutic vaccine, BPX-201, plus activating agent, AP1903, in patients with mCRPC. Patients will be screened within 8 weeks prior to first vaccine administration (4 weeks prior to leukapheresis). The trial design consists of 3 cohorts of 6 patients each, receiving escalating doses of BPX-201 of 10 million (M), 20M and 40M cells, respectively. Dose escalation will occur according to a 3+3 design. Patients will receive administration of BPX-201 every other week for 6 cycles (1 cycle equals 2 weeks). Approximately 1.6 mL of BPX-201 will be administered as 8 intradermal injections (200μL each) at each treatment visit. On the day following each vaccination, a single 40 mg dose of the activating agent, AP1903, will be administered via intravenous (IV) infusion over 2 hours.

Study Timeline

• Study First Submitted: 2013-03-21
• Study Start: 2013-04
• Study First Submitted QC: 2013-04-01
• Study First Posted: 2013-04-04
• Primary Completion: 2016-05
• Study Completion: 2017-09
• Status Verified: 2018-11
• Last Update Submitted: 2019-10-04
• Last Update Posted: 2019-10-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 19

Inclusion Criteria

1. Written informed consent

2. 18 years of age or older

3. Histologically confirmed, metastatic prostate cancer (positive bone scan and/or measurable disease on CT scan and/or MRI of the abdomen and pelvis).

4. Progressive disease after androgen deprivation, as defined by Prostate Cancer Working Group 2 and/or Response Evaluation Criteria in Solid Tumors criteria

5. Laboratory requirements:

   • Absolute neutrophil count (ANC) ≥ 1500/μL
   • Bilirubin < 1.5 x ULN
   • Hemoglobin > 8 g/dL
   • PSA > 2 ng/mL
   • Platelets > 100,000/µL
   • AST and ALT < 2.5 x ULN
   • Creatinine clearance ≥ 60mL/min
   • Testosterone < 50 ng/dL

6. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2 and life expectancy > 12 weeks

7. Patients receiving any other hormonal therapy, including any dose of megestrol acetate (Megace), Proscar (finasteride), any herbal product known to decrease PSA levels (e.g. Saw Palmetto, PC-SPES), or agents such as abiraterone, TAK700, MDV3100 as well as any systemic corticosteroid use, must discontinue the agent for at least four weeks prior to study treatment. Progressive disease as defined above must be documented after discontinuation of any hormonal therapy (with the exception of a LHRH agonist).

8. Prior radiation therapy must be completed > 4 weeks prior to enrollment and the patient must have recovered from all toxicity. Prior radiopharmaceuticals (strontium, samarium) must be completed ≥ 8 weeks prior to enrollment.

9. Because of the unknown potential risk to a gamete and/or developing embryo from these investigational therapies, patients must agree to use adequate contraception (barrier method for males) for the duration of study participation, and for three months after discontinuing therapy.

Exclusion Criteria

1. Prior chemotherapy for prostate cancer, with the exception of neo-adjuvant chemotherapy, because of the potential effect of chemotherapy on the immune system.

2. Prior sipuleucel-T treatment or investigational immunotherapy.

3. Prostate cancer pain requiring regularly scheduled narcotics.

4. Current treatment with systemic steroid therapy (inhaled/topical steroids are acceptable). Systemic corticosteroids must be discontinued for at least 4 weeks prior to first treatment.

5. Clinically active autoimmune disease.

6. Diagnosis of prostate cancer with neuroendocrine differentiation

7. Known presence of central nervous system metastases, pleural effusions or ascites

8. Medical or psychiatric illness that would, in the opinion of the investigator, preclude participation in the study or the ability of patients to provide informed consent for themselves.

9. Cardiovascular disease that meets one of the following: congestive heart failure (New York Heart Association Class III or IV), active angina pectoris, or recent myocardial infarction (within the last 6 months).

10. Concurrent or prior malignancy except for the following:

    • Adequately treated basal or squamous cell skin cancer
    • Adequately treated stage I or II cancer from which the patient is currently in complete remission
    • Any other cancer from which the patient has been disease-free for 5 years

11. Known HIV or other history of immunodeficiency disorder.

12. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or medical (e.g. infectious) illness.

13. Any underlying medical or psychiatric condition, which in the opinion of the investigator will make the administration of BPX-201 and AP1903 hazardous or obscure the interpretation of AEs, such as a condition associated with frequent diarrhea.

14. Any non-oncology vaccine therapy used for prevention of infectious diseases for up to 1 month before BPX-201

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
BPX-201	BPX-201 vaccine plus AP1903	BPX-201 vaccine plus AP1903

Primary Outcome Measures

Name	Time	Method
Number of Participants with adverse events as a measure of safety and tolerability	2 years	Safety will be measured through the monitoring of AEs, clinical laboratory parameters (hematology, serum chemistry, and urinalysis), vital sign measurements, and physical examinations.

Secondary Outcome Measures

Name	Time	Method
prostatic specific antigen	3 months	Measure PSA response and PSA doubling time as measured from PSA nadir through 12 weeks
Reduction in circulating tumor cells	2 years	Change from baseline in number of circulating tumor cells
Progression free survival	2 years	Rate of PFS
Response to chemotherapy after vaccine	2 years	Response to chemotherapy upon progression

Trial Locations

Locations (2)

UAB Comprehensive Cancer Center; 🇺🇸 Birmingham, Alabama, United States

Baylor Charles Sammons Cancer Center; 🇺🇸 Dallas, Texas, United States